Flow cytometric analysis of SK-BR-3 (Human breast adenocarcinoma epithelial cell, Left) / HeLa (Human cervix adenocarcinoma epithelial cell, Right) labelling B7-H2 antibody at 1/2000 dilution (0.1 μg) / (Red) compared with a Mouse IgG1, κ (Black) Isotype Control and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue). Goat Anti - Mouse IgG Alexa Fluor® 647 was used as the secondary antibody.
Negative control: HeLa
Mouse Anti-Human B7-H4 Antibody (S-3024)
Mouse Anti-Human B7-H4 Antibody (S-3024)
Price:
Regular price
$100 USD
Regular price
Sale price
$100 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | B7-H4 |
| Synonyms | V-set domain-containing T-cell activation inhibitor 1; B7 homolog 4 (B7-H4); B7h.5; Immune costimulatory protein B7-H4; Protein B7S1; T-cell costimulatory molecule B7x; B7H4; VTCN1 |
| Location | Cell membrane |
| Accession | Q7Z7D3 |
| Clone Number | S-3024 |
| Antibody Type | Mouse mAb |
| Isotype | IgG1,k |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | SK-BR-3 |
| Purification | Protein G |
| Concentration | 2 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1:2000 | Hu |
Background
B7-H4, also known as VTCN1 or B7x, is a ~50 kDa type-I trans-membrane glycoprotein of the B7 immunoglobulin superfamily that consists of an extracellular IgV-IgC domain pair, a single trans-membrane segment and a short cytoplasmic tail; it is expressed inducibly on antigen-presenting cells and constitutively on many epithelial cancers, where it acts as an immune-checkpoint ligand by binding an as-yet-unidentified receptor on activated CD4⁺ and CD8⁺ T cells, thereby arresting the cell cycle in G0/G1, suppressing IL-2 production and proliferation, and enabling tumours to evade immunity, making it an emerging target for cancer immunotherapy.
Picture
Picture
FC
